NCT02415985View on ClinicalTrials.gov

Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2019

Conditions
HIVTuberculosis
Interventions
DRUG

Lopinavir/r will be supplied by NHSO/GPO

200/50 mg tablet LPV/rtv

DRUG

Rifabutin

Trial Locations (4)

10330

Chest Division, Faculty of Medicine, Chulalongkorn University, Bangkok

HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok

Infectious Diseases, Faculty of Medicine, Chulalongkorn University, Bangkok

11000

Bamrasnaradura Infectious Diseases Institute, Nonthaburi

All Listed Sponsors
collaborator

Bamrasnaradura Infectious Diseases Institute

OTHER_GOV

collaborator

Chulalongkorn University

OTHER

lead

The HIV Netherlands Australia Thailand Research Collaboration

OTHER

NCT02415985 - Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly | Biotech Hunter | Biotech Hunter